Acute Myelogenous Leukemias with Recurrent Cytogenetic Abnormalities

You are here


This WHO group of Acute Myelogenous Leukemias is characterized by recurrent genetic abnormalities. The abnormalities are generally balanced translocations and have a high ratio  of complete remission and favorable prognosis. 

Sample Cases

Click here for instructions on how to download the free FCS Express Reader to view and manipulate the sample cases.


Case Name
(click on case name to open)
Comments  Size 

The following are recurring cytogenetic abnormalities seen in AML:

  • Acute myeloid leukemia with t(8;21)(q22;q22); (AML1/ETO)
  • Acute myelid leukemia with inv(16)(p13q22) or t(16;16)(p13q22); (CBFB/MYH11)
  • Acute promyelocytic leukemia (AML with t(15;17)(q22;q12); (PML/RARa)
  • Acute meyeloid leukemia with 11q23 (MLL) abnormalities


 Many of these genetic abnormalities are detected by reverse polymerase chain reaction (RT-PCR) which has a higher vity of ( X 10 5) than conventional cytogenetics (1 X 10 2)

Morphology and cytochemistry
Other relevant tests

Certain cytogenetic abnormalities are associated with very good outcomes (for example, the (15;17) translocation in acute promyelocytic leukemia). About half of AML patients have "normal" cytogenetics; they fall into an intermediate risk group. A number of other cytogenetic abnormalities are known to associate with a poor prognosis and a high risk of relapse after treatment

  Risk Category   Abnormality   5-year survival   Relapse rate


t(8;21), t(15;17), inv(16)

  70%   33%


Normal, +8, +21, +22, del(7q), del(9q), Abnormal 11q23, all other structural or numerical changes

  48%   50% 


5, -7, del(5q), Abnormal 3q, Complex cytogenetics

  15%    78%
Flow Diagnosis